Licencing and acquisitions

We look to expand our business through in-licensing and the acquisition of marketed, ready-to-market or late-stage assets. We are also interested in engaging in earlier stage research collaborations in our key focus areas. 

Innovative Medicine

Oncology and Pain are the main therapeutic focus areas of our R&D and we bring our commitment and expertise to our collaborations. Particularly we look for partnering opportunities to extend our pipeline and portfolio with innovative assets in both of these areas in different development stages.

Oncology

Orion oncology develops novel proprietary drugs for the treatment of cancer. Orion’s oncology R&D has a long history in the field. 
 
The two latest internal innovations are darolutamide, a novel anti-androgen and ODM-208, a first in-class CYP-11A1 inhibitor. 
 
Darolutamide has been designed for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. It was invented by Orion and is developed jointly with Bayer. 
 
ODM-208 is targeted for later stage prostatic cancer and in 2022 we entered into a global partnership with Merck/MSD for further development and commercialization.

In 2021 Orion started discovery collaboration with Alligator Bioscience for a novel bispecific antibody. In early 2023 collaboration was expanded to include second bispecific antibody discovery program. 
 
Read more about Early partnering and collaboration

Pain

Pain is one of the most frequently cited reasons for a patient to visit a healthcare provider. Pain also generates a significant societal burden in terms of e.g. healthcare utilization and lost productivity. The need for new, non-addictive treatment options is high and unmet. Orion wants to pursue pain treatment options that feature improved efficacy and safety profiles.  
 
In 2022 Orion entered into exclusive agreement with Jemincare for a novel non-opioid phase I ready drug candidate for the treatment of pain. Orion has exclusive global development and commercialization rights (excluding the Greater China area) for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain.
 
Read more about Early partnering and collaboration

Respiratory and Easyhaler® business 

Orion respiratory and Easyhaler® business is one of the core operations at Orion, with many business opportunities worldwide.  
 
Please visit our www.orionrespiratory.com to learn more. 

Generic Products, Biosimilars and Consumer Health products

Orion's portfolio consists of a range of over 300 generic prescription and consumer health products. We constantly rejuvenate our portfolio through in-licensing. The availability of these products varies from market to market, with main focus in Europe. Our partners appreciate our comprehensive coverage of the European markets and our commercialization capabilities.     

Animal Health

Orion's Animal Health division is a trusted innovator in the field of veterinary medicines and healthcare, complete with cutting-edge science and proud legacy of collaboration. 
 
As the Animal Health Division is pursuing robust growth, new partnering opportunities are welcome in both domestic and production animal healthcare.     
 
Please visit our www.orionpharmaanimalhealth.com to learn more.